Harnessing AI Capabilities to Disrupt Current P&R Models

Harnessing AI Capabilities to Disrupt Current P&R Models

Enhancing Pricing and Reimbursement Strategies by Leveraging AI Capabilities

Discover how Artificial Intelligence (AI) is revolutionising the pharmaceutical industry's approach to pricing and reimbursement (P&R) in our latest report, Harnessing AI Capabilities to Disrupt Current P&R Models. This report delves into the transformative role of AI in enhancing pricing models, optimising market access strategies, and streamlining health technology assessments.

With insights from industry experts and a focus on cutting-edge AI applications, learn how predictive analytics, machine learning, and generative AI are being leveraged to improve decision-making processes, scenario planning, and risk assessments. Understand the impact of regulatory changes like the Inflation Reduction Act and the adoption of Joint Clinical Assessments on pharma's pricing and reimbursement landscape. Explore case studies from leading companies such as Amgen, Novartis, and Gilead Sciences, showcasing successful AI integration in their operations.

Companies

Amgen, Novartis, GSK, Gilead Sciences, Cigna, Alexion, Aetna, OpenAI, Acodis, Huma.AI, Inpharmation, Decisive Consulting, Glass Box Analytics, Harvard Pilgrim, Konplik, OKRA Technologies, RQM+, Sorcero, Thermo Fisher Scientific, Ydata